Tags

Type your tag names separated by a space and hit enter

Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment.
Cold Spring Harb Perspect Med. 2019 07 01; 9(7)CS

Abstract

Hepatitis E virus (HEV) genotype (gt)3 and 4 infections are prevalent in industrialized and high-income countries. Although most HEV gt3 and gt4 infections are clinically silent, acute infection may be symptomatic in some patients. In persons with underlying liver disease and in elderly men, HEV infections may present as acute or acute-on-chronic liver failure. Chronic hepatitis may develop in immunosuppressed individuals, including transplant recipients, human immunodeficiency virus (HIV)-infected patients, and persons with hematologic malignancy undergoing chemotherapy, and may progress to life-threatening liver cirrhosis. Extrahepatic manifestations of infection may include neurological and renal disease. Although there is no approved specific therapy for the treatment of acute or chronic HEV gt3 or gt4 infection, off-label use of ribavirin appears to be capable of eliminating chronic HEV infection, and may reduce disease severity in patients suffering from acute liver failure.

Authors+Show Affiliations

Department of Nephrology and Organ Transplantation, Université Paul Sabatier, Toulouse 31059, France.Department of Medicine I, University Medical Center Hamburg-Eppendorf, Hamburg 20251, Germany.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29735575

Citation

Kamar, Nassim, and Sven Pischke. "Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment." Cold Spring Harbor Perspectives in Medicine, vol. 9, no. 7, 2019.
Kamar N, Pischke S. Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment. Cold Spring Harb Perspect Med. 2019;9(7).
Kamar, N., & Pischke, S. (2019). Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment. Cold Spring Harbor Perspectives in Medicine, 9(7). https://doi.org/10.1101/cshperspect.a031872
Kamar N, Pischke S. Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment. Cold Spring Harb Perspect Med. 2019 07 1;9(7) PubMed PMID: 29735575.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment. AU - Kamar,Nassim, AU - Pischke,Sven, Y1 - 2019/07/01/ PY - 2021/07/01/pmc-release PY - 2018/5/8/pubmed PY - 2020/9/18/medline PY - 2018/5/9/entrez JF - Cold Spring Harbor perspectives in medicine JO - Cold Spring Harb Perspect Med VL - 9 IS - 7 N2 - Hepatitis E virus (HEV) genotype (gt)3 and 4 infections are prevalent in industrialized and high-income countries. Although most HEV gt3 and gt4 infections are clinically silent, acute infection may be symptomatic in some patients. In persons with underlying liver disease and in elderly men, HEV infections may present as acute or acute-on-chronic liver failure. Chronic hepatitis may develop in immunosuppressed individuals, including transplant recipients, human immunodeficiency virus (HIV)-infected patients, and persons with hematologic malignancy undergoing chemotherapy, and may progress to life-threatening liver cirrhosis. Extrahepatic manifestations of infection may include neurological and renal disease. Although there is no approved specific therapy for the treatment of acute or chronic HEV gt3 or gt4 infection, off-label use of ribavirin appears to be capable of eliminating chronic HEV infection, and may reduce disease severity in patients suffering from acute liver failure. SN - 2157-1422 UR - https://www.unboundmedicine.com/medline/citation/29735575/Acute_and_Persistent_Hepatitis_E_Virus_Genotype_3_and_4_Infection:_Clinical_Features_Pathogenesis_and_Treatment_ DB - PRIME DP - Unbound Medicine ER -